Asset Details
Do you wish to reserve the book?
N w ‐Hydroxy L‐Arginine ( NOHA ): A Promising Biomarker of Response to Neoadjuvant Therapy in the Management of Triple Negative Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
N w ‐Hydroxy L‐Arginine ( NOHA ): A Promising Biomarker of Response to Neoadjuvant Therapy in the Management of Triple Negative Breast Cancer
Do you wish to request the book?
N w ‐Hydroxy L‐Arginine ( NOHA ): A Promising Biomarker of Response to Neoadjuvant Therapy in the Management of Triple Negative Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
N w ‐Hydroxy L‐Arginine ( NOHA ): A Promising Biomarker of Response to Neoadjuvant Therapy in the Management of Triple Negative Breast Cancer
2026
Overview
Oncologists lack effective point-of-care biomarkers to rapidly adapt curative-intent triple negative breast cancer (TNBC) neoadjuvant therapy (NT). Previous work reveals that N
-hydroxy-L-Arginine (NOHA) is an easily measured and sensitive plasma-based biomarker for breast cancer hormone receptor status, disease stage, and grade, with reduced levels correlating with the presence of estrogen receptor negative and high-risk disease.
This pilot study examined NOHA's potential as a marker of both TNBC disease presence and treatment exposure to curative intent TNBC NT, including evaluation of the relationship between longitudinal NOHA normalization and measures of pathologic response.
NOHA concentration was assessed pre-NT and then longitudinally at five timepoints, including pre- and post-operatively, among 31 TNBC patients undergoing definitive surgery following receipt of NT. NOHA concentrations were low pre-NT and increased progressively toward healthy control levels during and after neoadjuvant therapy and post-operatively in all patients, yet showed no difference comparing those achieving pathologic complete response versus pathologic partial response or stable disease. Levels did not vary based on receipt of pembrolizumab, clinical characteristics, or presence of non-cancer comorbidities.
These findings support NOHA's potential as a marker of disease presence and treatment exposure rather than differential response. Larger validation studies are needed to determine whether serial levels can be used to optimize treatment decision-making or improve outcomes in high-risk populations.
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Arginine - analogs & derivatives
/ Female
/ Humans
/ Neoadjuvant Therapy - methods
/ Pathologic Complete Response
/ Triple Negative Breast Neoplasms - blood
/ Triple Negative Breast Neoplasms - drug therapy
